What was the market valuation of the UK peripheral neuropathy market in 2024?

The market valuation of the UK peripheral neuropathy market was $138.6 Million in 2024. Read More

What is the projected market valuation for the UK peripheral neuropathy market by 2035?

The projected market valuation for the UK peripheral neuropathy market is $420.38 Million by 2035. Read More

What is the expected CAGR for the UK peripheral neuropathy market during the forecast period 2025 - 2035?

The expected CAGR for the UK peripheral neuropathy market during the forecast period 2025 - 2035 is 10.61%. Read More

Which companies are considered key players in the UK peripheral neuropathy market?

Key players in the UK peripheral neuropathy market include Pfizer Inc, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Sanofi S.A., and Mylan N.V. Read More

What was the market size for Diabetic Peripheral Neuropathy in 2024?

The market size for Diabetic Peripheral Neuropathy was $70.44 Million in 2024. Read More

What is the projected market size for Non-Pharmacological Therapies by 2035?

The projected market size for Non-Pharmacological Therapies is $150.0 Million by 2035. Read More

What segment accounted for the highest market size in the UK peripheral neuropathy market in 2024?

In 2024, the segment that accounted for the highest market size was Diabetic Peripheral Neuropathy, valued at $70.44 Million. Read More

What is the expected market size for Hospitals and Clinics by 2035?

The expected market size for Hospitals and Clinics is projected to reach $213.12 Million by 2035. Read More

How does the market size for Chemotherapy-induced Peripheral Neuropathy compare between 2024 and 2035?

The market size for Chemotherapy-induced Peripheral Neuropathy was $34.32 Million in 2024 and is projected to grow to $104.12 Million by 2035. Read More

UK Peripheral Neuropathy Market

Q: What are the main types of peripheral neuropathy segments in the UK market?

The main types of peripheral neuropathy segments in the UK market include Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and HIV/AIDS Associated Peripheral Neuropathy. Read More

ID: MRFR/HC/49643-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Peripheral Neuropathy Market Research Report By Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies, Others), and By End-user (Hospitals and Clinics, Ambulatory Centers, Others) - Growth & Industry Forecast 2025 To 2035

UK Peripheral Neuropathy Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Diabetic Peripheral Neuropathy
  2. 4.1.2 Chemotherapy-induced Peripheral Neuropathy
  3. 4.1.3 Idiopathic Peripheral Neuropathy
  4. 4.1.4 HIV/AIDS Associated Peripheral Neuropathy
2. 4.2 Industrial Automation & Equipment, BY Treatment (USD Million)
  1. 4.2.1 Pharmacological Therapies
  2. 4.2.2 Non-Pharmacological Therapies
  3. 4.2.3 Others
3. 4.3 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.3.1 Hospitals and Clinics
  2. 4.3.2 Ambulatory Centers
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca PLC (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi S.A. (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Mylan N.V. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY TREATMENT
4. 6.4 UK MARKET ANALYSIS BY END USER
5. 6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type (USD Million, 2025-2035)

Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy

Industrial Automation & Equipment By Treatment (USD Million, 2025-2035)

Pharmacological Therapies
Non-Pharmacological Therapies
Others

Industrial Automation & Equipment By End User (USD Million, 2025-2035)

Hospitals and Clinics
Ambulatory Centers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓